Fluoxetine treatment of acral lick dermatitis in dogs: a placebo-controlled randomized double blind trial

Depress Anxiety. 1998;8(1):21-3.

Abstract

The aim of the study was to assess the efficacy and tolerability of fluoxetine treatment of acral lick dermatitis (ALD) in dogs and to investigate ALD as an animal model of obsessive-compulsive disorder (OCD). Sixty-three dogs with ALD were treated with fluoxetine 20 mg daily, or placebo, for 6 weeks. In the fluoxetine group, owners rated both appearance of the lesion (t = 10.2, df = 29, P < 0.0001) and licking behavior (t = 10.2, df = 29, P < 0.0001) as significantly improved by the end of the trial. Veterinarian-rated pre- and post-treatment photographs showed statistically significant improvement in the fluoxetine group (mean = 2.55). There were no significant changes in the placebo group as rated by owners and veterinarians. These results demonstrate the efficacy of fluoxetine in the treatment of ALD and lend further support to ALD as an animal model of OCD.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Antidepressive Agents, Second-Generation / pharmacology
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Dermatitis / diagnosis
  • Dermatitis / etiology
  • Dermatitis / veterinary*
  • Disease Models, Animal
  • Dog Diseases / diagnosis
  • Dog Diseases / drug therapy*
  • Dogs
  • Double-Blind Method
  • Female
  • Fluoxetine / pharmacology
  • Fluoxetine / therapeutic use*
  • Grooming / drug effects
  • Male
  • Mental Disorders / veterinary
  • Obsessive-Compulsive Disorder / complications
  • Reproducibility of Results
  • Treatment Outcome

Substances

  • Antidepressive Agents, Second-Generation
  • Fluoxetine